Key result
CHF is linked to ~37% lower mexiletine clearance, worsening with NYHA class severity.
Why the study?
Does congestive heart failure reduce mexiletine clearance in inpatients receiving mexiletine therapy?
Observational (n=584)
Yes
Does congestive heart failure reduce mexiletine clearance in inpatients receiving mexiletine therapy?
Absolute Event Rate: 0.246% vs 0.393%
p-value: p=<0.05
Congestive heart failure significantly reduces mexiletine clearance, necessitating dose adjustments and careful monitoring in this population.
May support cautious mexiletine dosing in HF inpatients; hypothesis-generating and requires prospective validation.
OBJECTIVE: The goal of this study was to evaluate the influence of congestive heart failure (CHF) on the clearance of mexiletine. METHODS: The mexiletine clearance/bioavailability (CL/F) ratio was estimated in 584 inpatients receiving mexiletine therapy. The study population consisted of 210 patients with CHF [CHF group; 116 inpatients with New York Heart Association (NYHA) class I-II (group NYHA I-II) CHF and 94 inpatients with NYHA class III-IV (group NYHA III-IV) CHF] and 374 inpatients without CHF (Non-CHF group). Serum levels of mexiletine were determined by high performance liquid chromatography (HPLC). RESULTS: Mexiletine clearance was significantly lower in the CHF group when compared with the Non-CHF group (0.264+/-0.093 vs. 0.393+/-0.082 l/h/kg, mean+/-S.D., p<0.05). Further, the CL/F ratio was 50% lower in group NYHA III-IV when compared with the Non-CHF group, and the CL/F ratio tended to change in inverse proportion to NYHA class. CONCLUSION: CHF status significantly affects mexiletine clearance. Therefore, dose adjustments and careful monitoring are likely required in CHF patients receiving mexiletine.
No takes yet. Share an insight, caveat, or question.
Kobayashi et al. (2006) conducted an observational in Ventricular arrhythmias (n=584). Congestive heart failure vs. Patients without congestive heart failure was evaluated on Mexiletine clearance/bioavailability (CL/F) ratio (l/h/kg) (p=<0.05). Congestive heart failure significantly reduced mexiletine clearance compared to patients without heart failure (0.246 vs 0.393 l/h/kg, p<0.05), with clearance decreasing proportionally to NYHA class severity.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: